Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
57
resultados
Última actualización
13/07/2026 [11:39:00]
Resultados 50 a 57 de 57
Resumen de: CN121731448A
The invention discloses application of INO80E in preparation of an anti-atherosclerosis medicine, and belongs to the technical field of biological medicines. The invention reveals for the first time that INO80E can interact with histone deacetylase 1 (HDAC1) so as to deacetylate a transcription factor YY1, so that vascular endothelial cell apoptosis is inhibited, and the purpose of delaying an atherosclerosis process is achieved. Experiments prove that the expression level of INO80E in an atherosclerosis model is remarkably reduced; overexpression of INO80E can effectively reverse endothelial cell apoptosis induced by oxidized low-density lipoprotein (ox-LDL) and restore expression balance of anti-apoptotic protein Bcl-2 and pro-apoptotic protein BAX. Therefore, the INO80E can be used as a brand new drug target for treating or preventing atherosclerosis related diseases, can be used for preparing diagnostic reagents or drugs, and has the advantages of no equipment dependence and strong targeting.
Resumen de: CN121718626A
The invention relates to the technical field of biological medicine, in particular to a marker for diagnosis and treatment of heart failure and application of the marker, and aims to solve the problem that in the prior art, systematic and deep research on CTHRC1 in a pressure overload model closer to human heart failure pathology is lacked. The application proves that the expression level of the CTHRC1 is obviously up-regulated no matter in heart tissues and serum of an animal model or serum of a clinical sample, so that the reliability and the sensitivity of the CTHRC1 as the heart failure biomarker are proved, and a brand-new diagnostic marker directly related to fibrosis pathology is provided for the heart failure; in addition, it is also clearly proposed that the CTHRC1 monoclonal antibody is used for preparing a medicine for treating heart failure, and the CTHRC1 monoclonal antibody can neutralize and effectively block the specific biological function activity of a CTHRC1 immunogen through high binding affinity, and can become a new treatment target for relieving or reversing cardiac fibroblast activation and cardiac fibrosis.
Resumen de: CN121718536A
The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.
Resumen de: CN121700057A
The invention discloses an SNP (Single Nucleotide Polymorphism) marker combination for evaluating venous thromboembolism, a product and application, and relates to the technical field of in-vitro detection. The invention discloses an SNP (Single Nucleotide Polymorphism) marker combination, which comprises an rs201381904, an rs587776397, an rs146922325, an rs199469469, an rs199469503, an rs1576170616, an rs121918474, an rs2107279407, an rs1799762, an rs16984852 and an rs1801133, and is characterized in that the rs587776397, the rs146922325, the rs199469469, the rs199469503, the rs1576170616, the The SNP marker combination covers a plurality of physiological pathways such as coagulation, anticoagulation, fibrinolysis, folic acid metabolism and the like, and compared with the prior art that only a few loci are detected, evaluation is more comprehensive. The detection method provided by the invention can be realized based on a mature PCR technology, and is easy to popularize and apply in a clinical examination laboratory.
Resumen de: WO2026055844A1
A system for early warning of coronary heart disease. A computer device comprises a memory, a processor, and a computer program stored on the memory. The processor executes the computer program to implement the following steps: receiving methylation level data of a DNA methylation marker combination of a potential coronary heart disease patient and a healthy control sample, establishing a mathematical model, and determining a threshold; and inputting methylation level data of the DNA methylation marker combination of a subject to be tested and substituting same into the mathematical model to obtain a detection index, and comparing the detection index with the threshold to obtain a conclusion of whether a sample to be tested belongs to the potential coronary heart disease patient or the healthy control. The present invention has important scientific significance and clinical application value in early warning of coronary heart disease and diagnosis and treatment of coronary heart disease.
Resumen de: WO2026057057A1
Provided are a group of biomarkers for diagnosing hypertension in children, a test kit, and a use thereof. By means of collecting tongue coating/intestinal samples of obese children with hypertension, obese children, and healthy people, performing metagenomic sequencing, and using bioinformatics to calculate statistics on sequencing data, disease-related tongue/intestinal flora is found, and the tongue/intestinal flora is integrated with disease information to obtain a combination of flora biomarkers. A binary classification prediction model constructed by means of said combination can maximally detect obese children with hypertension.
Nº publicación: CN121687206A 17/03/2026
Solicitante:
HUNAN QINGGENG BIOLOGICAL INDUSTRY INNOVATION RESEARCH INST CO LTD
\u6E56\u5357\u7701\u9752\u8015\u751F\u7269\u4EA7\u4E1A\u521B\u65B0\u7814\u7A76\u9662\u6709\u9650\u516C\u53F8
Resumen de: CN121687206A
The invention discloses a microRNA (Ribonucleic Acid) prediction model and a prediction kit for identifying myocardial infarction. According to the invention, six microRNAs with stable and specific expression modes in peripheral blood of an AMI patient are taken as combined markers and are used for identifying the onset risk of AMI. The microRNAs may have abnormal expression before myocardial infarction attack, have good detection stability in blood, and are important supplements for myocardial necrosis markers such as traditional troponin and the like. By capturing the early expression change of microRNA in peripheral blood, high-risk individuals can be subjected to prospective identification before typical symptoms appear, and a time window is provided for active intervention.
BOPI
Sede Electrónica
